Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 12/20 | 0.58 |
| ▸ | PLA2G2A | P14555 | 3/20 | 0.49 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1757395 | 0.89 | PTGDR2 (0.60) | PTGDR2PLA2G2APLA2G1BMEN1KMT2A | |
| SCHEMBL1759164 | 0.87 | PTGDR2 (0.61) | PTGDR2AKR1B1 | |
| SCHEMBL1757715 | 0.86 | PTGDR2 (0.66) | PTGDR2 | |
| SCHEMBL1759392 | 0.86 | PTGDR2 (0.62) | PTGDR2 | |
| SCHEMBL1759190 | 0.85 | PTGDR2 (0.68) | PTGDR2 | |
| SCHEMBL1757752 | 0.81 | PTGDR2 (0.78) | PTGDR2PLA2G2APLA2G1B | |
| SCHEMBL1757779 | 0.80 | PTGDR2 (0.57) | PTGDR2POLBAKR1B1 | |
| SCHEMBL1757819 | 0.79 | PTGDR2 (0.62) | PTGDR2PLA2G2APLA2G1BAKR1B1 | |
| SCHEMBL1757478 | 0.76 | PTGDR2 (0.46) | PTGDR2AKR1B1 | |
| SCHEMBL318378 | 0.76 | PTGDR2 (0.66) | PTGDR2PLA2G2APLA2G1BMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105509-A1 | INDOLE BASED RECEPTOR CRTH2 ANTAGONISTS | WYETH, LLC (US) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105509-A1 | INDOLE BASED RECEPTOR CRTH2 ANTAGONISTS | HRH2, CRHR2, CRHR1 | PTGDR2 13/4885PLA2G2A 1208/4885PLA2G1B 1932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.